Pediatric Blood and Marrow Transplant Program, Duke University Medical Center, Durham, North Carolina 27710, USA.
Transfusion. 2012 Feb;52(2):272-83. doi: 10.1111/j.1537-2995.2011.03278.x. Epub 2011 Aug 2.
Engraftment failure and delays, likely due to diminished cord blood unit (CBU) potency, remain major barriers to the overall success of unrelated umbilical cord blood transplantation (UCBT). To address this problem, we developed and retrospectively validated a novel scoring system, the Cord Blood Apgar (CBA), which is predictive of engraftment after UCBT.
In a single-center retrospective study, utilizing a database of 435 consecutive single cord myeloablative UCBTs performed between January 1, 2000, to December 31, 2008, precryopreservation and postthaw graft variables (total nucleated cell, CD34+, colony-forming units, mononuclear cell content, and volume) were initially correlated with neutrophil engraftment. Subsequently, based on the magnitude of hazard ratios (HRs) in univariate analysis, a weighted scoring system to predict CBU potency was developed using a randomly selected training data set and internally validated on the remaining data set.
The CBA assigns transplanted CBUs three scores: a precryopreservation score (PCS), a postthaw score (PTS), and a composite score (CS), which incorporates the PCS and PTS values. CBA-PCS scores, which could be used for initial unit selection, were predictive of neutrophil (CBA-PCS ≥ 7.75 vs. <7.75, HR 3.5; p < 0.0001) engraftment. Likewise, CBA-PTS and CS scores were strongly predictive of Day 42 neutrophil engraftment (CBA-PTS ≥ 9.5 vs. <9.5, HR 3.16, p < 0.0001; CBA-CS ≥ 17.75 vs. <17.75, HR 4.01, p < 0.0001).
The CBA is strongly predictive of engraftment after UCBT and shows promise for optimizing screening of CBU donors for transplantation. In the future, a segment could be assayed for the PTS score providing data to apply the CS for final CBU selection.
植入失败和延迟,可能是由于脐带血单位(CBU)效力降低所致,仍是无关脐带血移植(UCBT)总体成功的主要障碍。为了解决这个问题,我们开发并回顾性验证了一种新的评分系统,即脐带血 Apgar(CBA),该系统可预测 UCBT 后的植入情况。
在一项单中心回顾性研究中,利用 2000 年 1 月 1 日至 2008 年 12 月 31 日期间进行的 435 例连续单脐带血清髓性 UCBT 的数据库,在冷冻保存前和冷冻保存后,对移植物变量(总核细胞、CD34+、集落形成单位、单核细胞含量和体积)与中性粒细胞植入进行了初步相关性分析。随后,基于单变量分析中危害比(HR)的幅度,使用随机选择的训练数据集开发了一种加权评分系统,以预测 CBU 的效力,并在剩余数据集中进行内部验证。
CBA 为移植的 CBU 分配三个分数:冷冻前分数(PCS)、解冻后分数(PTS)和综合分数(CS),其中包含 PCS 和 PTS 值。CBA-PCS 分数可用于初始单位选择,可预测中性粒细胞(CBA-PCS≥7.75 与 <7.75,HR3.5;p<0.0001)植入。同样,CBA-PTS 和 CS 分数强烈预测第 42 天的中性粒细胞植入(CBA-PTS≥9.5 与 <9.5,HR3.16,p<0.0001;CBA-CS≥17.75 与 <17.75,HR4.01,p<0.0001)。
CBA 强烈预测 UCBT 后的植入情况,并有望优化 CBU 供体的筛选,以进行移植。在未来,可以对 PTS 分数进行分析,为最终 CBU 选择提供 CS 数据。